This is the first prospective real-world analysis aiming to clarify the long-term effectiveness of a CGRP mAb-fremanezumab, against the ligand in the treatment refractory CM patients with a poor/no clinical response to a CGRP mAb against the receptor–erenumab. This evidence concerns the gene CALCA and cutaneous mastocytosis.